Form 4: Vertex Pharmaceuticals Executive Amit Sachdev Reports Changes in Beneficial Ownership
SEC Form 4 Filing
EVP, Chief Patient & External Affairs Officer of Vertex Pharmaceuticals, Amit Sachdev, reports changes in beneficial ownership of company stock.
Summary
- On June 5, 2024, Amit Sachdev, EVP, Chief Patient & External Affairs Officer of Vertex Pharmaceuticals, reported changes in beneficial ownership of the company's common stock.
- Sachdev disposed of 4,600 shares of common stock through a gift.
- Sachdev directly owns 57,290 shares of common stock.
- Sachdev indirectly owns 882 shares of common stock through a 401(k).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting changes in beneficial ownership, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions.
Stakeholder Impact
- The transaction may be of interest to shareholders as it provides insight into the actions of company executives.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction involving Vertex Pharmaceuticals common stock. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.